CN1410110A - Application of Chinese medicine containing sarcandra for treating side effect of anticancer medicine - Google Patents
Application of Chinese medicine containing sarcandra for treating side effect of anticancer medicine Download PDFInfo
- Publication number
- CN1410110A CN1410110A CN 02144873 CN02144873A CN1410110A CN 1410110 A CN1410110 A CN 1410110A CN 02144873 CN02144873 CN 02144873 CN 02144873 A CN02144873 A CN 02144873A CN 1410110 A CN1410110 A CN 1410110A
- Authority
- CN
- China
- Prior art keywords
- herba sarcandrae
- extract
- herba
- side effect
- sarcandrae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine in the form of oil-applied medicine or injection for treating the by-effect caused by anticancer medicines features that it contains Sarcandra glabra. It can improve immunity and treat the thrombocytopenia caused by radiotherapy and chemicotherapy.
Description
Technical field
The present invention relates to a kind of new purposes that contains the Herba Sarcandrae Chinese medicine preparation, particularly a kind of contain the Herba Sarcandrae Chinese medicine preparation as preparation put in tumor, the application of the ideal medicament of treatment cancer therapy drug side effect in the amic therapy method.
Background technology
Herba Sarcandrae [Sarcandra glabra (Thunb.) Nakai] is the dry Herb of Chloranthaceae Herba Pileae Scriptae platymiscium, has another name called Herba Pileae Scriptae.Nature and flavor suffering, hardship, tepor have anti-inflammation, dispelling wind and removing obstruction in the collateral, the effect of blood circulation promoting and dispersing pathogen accumulation.
At present, the leaching preparation that adopts Herba Sarcandrae to make has extract oral agent and Chinese medicine.The extract oral agent can be made dosage forms such as fluid extract, extracta sicca, oral liquid, electuary, tablet, hard capsule, soft capsule, microencapsulation; Chinese medicine can be made dosage forms such as injection with small volume, Da Rong injection.
The XUEKANG KOUFUYE that Jingang Pharmaceutical Co., Ltd., Dalian produces, it is the Herba Sarcandrae oral liquid, be the pure extract oral agent that primary raw material is made with the Herba Sarcandrae dry extract powder exactly, [function with cure mainly] of " XUEKANG KOUFUYE " that Chinese Pharmacopoeia was collected in the version in 2000 indicated, acting as of this medicine: blood circulation promoting and blood stasis dispelling, dispersing swelling and dissipating binds, cooling blood for hemostasis.Be used for bleeding due to blood-heat, ecchymosis; Constitutional and secondary thrombocytopenic purpura.Blood is capable to overflow between skin, and livid purple speckle or speckle appear in skin, are called purpura, belongs to tcm internal medicine miscellaneous diseases category.A large amount of clinical practices prove, XUEKANG KOUFUYE has the characteristics of total effective rate height (84.2%) to QI failing to control blood and type of hyperactivity of fire caused by deficiency of YIN purpura (constitutional and secondary thrombocytopenic purpura), and can significantly improve clinical symptoms, it is determined curative effect, remarkable in process of clinical application, steady quality, it is little to use convenience, safety, toxic and side effects, so it obtains wideling popularize application clinically.According to " herbal species conservation regulation " issued by the State Council regulation, this XUEKANG KOUFUYE has been listed in national secondary Chinese medicine protection kind [guaranteeing No. the 0511st, word in (2001) traditional Chinese medicines].This Herba Sarcandrae oral liquid can also adopt the Herba Sarcandrae fluid extract to make; Adopt the Herba Sarcandrae fluid extract also can make dosage forms such as soft capsule and microcapsule; Can certainly adopt Herba Sarcandrae dry extract to make dosage forms such as hard capsule, electuary.
The Herba Sarcandrae extractum of selling on the market in addition is mainly used in pneumonia, appendicitis, cellulitis.The ZHONGJIEFENG PIAN that also useful Herba Sarcandrae extractum is processed into is mainly used in pneumonia, appendicitis, cellulitis and belongs to pyretic toxicity Yong Sheng disease person, and can be used for assistant treating cancer.The swollen joint injection with small volume that also useful Herba Sarcandrae extract is made is mainly used in pneumonia, bacillary dysentery, gastroenteritis, abscess, and rheumatic, rheumatoid arthritis, arthralgia etc.
According to the relevant reported in literature in home and abroad, in tumor therapeutic procedure, put, the thrombocytopenic main cause after the chemotherapy is: oncotherapy is used puts, chemotherapeutics is in the growth of killing, suppress tumor cell, also disturbed the normal immune system of human body, make its disorder and function reduction, directly cause platelet to descend, promptly due to the side effects of pharmaceutical drugs.This cancer therapy drug causes platelet to descend does not have specific Drug therapy always.The low dose of dexamethasone of the employing that has clinically (DXM) is treated, but curative effect is unsatisfactory, and these product easily cause diabetes and class Cushing's syndrome symptom than heavy dose, and it is stronger to the hypothalmus-pituitary-adrenal axis inhibitory action, thereby often delays the chemotherapy time; The method of the employing platelet transfusion that also has is replenished hematoblastic quantity, but medical expense is higher, and individual patient also is easy to generate platelet antibody, delay treatment.
Summary of the invention
The purpose of this invention is to provide a kind of application that contains the Herba Sarcandrae Chinese medicine preparation as preparation treatment cancer therapy drug side effect medicine, promptly make full use of the blood circulation promoting and blood stasis dispelling that contains the Herba Sarcandrae Chinese medicine preparation, dispersing swelling and dissipating binds, cooling blood for hemostasis and can strengthen the effect of immune function of human body is as the ideal medicament that the antagonism tumor of treatment cancer therapy drug side effect is put, platelet descends in the chemotherapy.
The object of the present invention is achieved like this: used Herba Sarcandrae Sarcandra glabra (Thunb.) Nakai is a Chloranthaceae Herba Pileae Scriptae platymiscium Herba Pileae Scriptae, adopt raw material Herba Sarcandrae herb decoction pieces to make fluid extract or dry extract, make every 1g fluid extract or dry extract be equivalent to raw material Herba Sarcandrae herb decoction pieces 10g, with Herba Sarcandrae fluid extract or dry extract is that primary raw material is made extract oral agent application, make the Chinese medicine injection with small volume with Herba Sarcandrae herb decoction pieces extract and use, make every 2ml injection contain raw material Herba Sarcandrae herb decoction pieces and be equivalent to 4g.
Above-mentioned extract oral agent is used can make dosage forms such as fluid extract, extracta sicca, oral liquid, electuary, tablet, hard capsule, soft capsule, microencapsulation.
Above-mentioned Chinese medicine can be made dosage forms such as injection with small volume, high-capacity injection.
The present invention contains the Herba Sarcandrae Chinese medicine preparation as preparation treatment cancer therapy drug side effect medicine, its Main Ingredients and Appearance Herba Sarcandrae, and in 1 67 pages of record of Chinese Pharmacopoeia version in 2000, Herba Sarcandrae has anti-inflammation, dispelling wind and removing obstruction in the collateral, the effect of blood circulation promoting and dispersing pathogen accumulation.It is the Chinese medicine preparation of Main Ingredients and Appearance that corresponding report also disclosed with the Herba Sarcandrae---Herba Sarcandrae oral liquid (being XUEKANG KOUFUYE), ZHONGJIEFENG PIAN, Herba Sarcandrae injection with small volume etc. all have identical effect, end to see and have the report for the treatment of the cancer therapy drug side effect.Theory of Chinese medical science is thought: oncotherapy is used puts, chemotherapeutics in the growth of killing, suppress tumor cell, also disturbed the normal immune system of human body, make its disorder and function reduction, directly cause platelet to descend.
By measure XUEKANG KOUFUYE to put, the test of platelet and leukocytic influence due to the chemotherapy, for containing the Herba Sarcandrae Chinese medicine preparation in clinical practice, opened up new purposes as preparation treatment cancer therapy drug side effect medicine.In this test method:
Be subjected to the reagent thing: the XUEKANG KOUFUYE that adopts Jingang Pharmaceutical Co., Ltd., Dalian to produce, i.e. Herba Sarcandrae oral liquid.
Compound method: get stock solution and add an amount of sterilization and be diluted with water to desired concn, every Mus irritates that body of stomach is long-pending to be 0.5ml every day.Every group of 30 mices of test group and positive controls, negative control respectively is two groups.
Dosage is provided with: the high, medium and low dosage of XUEKANG KOUFUYE is 16ml/kg, 8ml/kg, 4ml/kg, is equivalent to 200,100,50 times of clinical using dosage respectively.
Dosage regimen: adopt gastric infusion, beginning from experiment is to be administered once every day, and platelet and leukocyte recover normal in blood sample, generally need be total to administration 18 times in continuous 18 days.
Result of the test:
XUEKANG KOUFUYE is to platelet and leukocytic result of the test due to the chemotherapeutic 5Fu: experiment platelet and leukocyte between 6-9 days obviously reduce, the high, medium and low dosage group of XUEKANG KOUFUYE have in various degree the antagonism platelet and the effect of low leukocyte counts, and each administration group platelet and leukocyte return to normally also apparent in view.
XUEKANG KOUFUYE is to caused by radiation platelet and leukocytic result of the test: experiment platelet and leukocyte between 6-9 days obviously reduce, the high, medium and low dosage group of XUEKANG KOUFUYE have in various degree the antagonism platelet and the effect of low leukocyte counts, and each administration group platelet and leukocyte return to normally also apparent in view.
Experiment conclusion:
The oral dose that XUEKANG KOUFUYE adopts clinical use has tangible antagonism to thrombocytopenia due to radiotherapy or the chemotherapy.Above-mentioned experiment provides the experimental data to purebred mice, for clinical radiotherapy or chemotherapy provide foundation.Use XUEKANG KOUFUYE and carry out preliminary clinical experiment, to the patient that platelet behind the 20 example treatment chemotherapy of tumors descends, no matched group compares, and its observed result is as follows:
1, clinical data
Patient's entry standard: platelet after the chemotherapy＜70 * 10
9.L
-1
Component: two groups of stochastic sampling
One group (blood health group): 20 examples, male's 16 examples, women's 4 examples, age 28-64 year.
Usage and dosage: each oral 10-20ml, every day 3 times, take continuously to normal (fail normal person to the chemotherapy 30 days end).
Organize separately same.
Check platelet in the treatment weekly 2 times.
Observe: (1), treatment back 1 all every group of platelet meansigma methodss.
(2), platelet rises to 100 * 10
9.L
-1The required time.
(3), 30 days platelet rise to normal routine number after the chemotherapy.
Data are learned processing by statistics and are checked and x with t
2Check---be used for the effective percentage test.
2, result: see the following form, notable difference (P＜0.01) is arranged.
| Before the treatment | After the treatment | Rise to 100 * 10 9.L -1Required meta natural law | 28 days PLT rise to positive common practice number after the chemotherapy | |
| Blood health group | ?40.5±5.2 | ?90±10.0 | ????10.0 | ?????18(90.0％) |
| Other group | ?42.0±3.0 | ?59±4.0 | ????18.0 | ?????10(50.0％) |
Annotate: other is organized to not changing former clinical application person.
3, discuss: the result shows: XUEKANG KOUFUYE obviously has the platelet of making and raises, and shortening rises to normal required time (in the meta natural law), and do not find other untoward reaction such as obvious hepatic renal dysfunction and blood system illness, so can think that such contains the agent of Herba Sarcandrae extract oral and injection can be used as treatment cancer therapy drug side effect medicine.
This shows that containing Herba Sarcandrae is extract oral agent and the injection that primary raw material is made, and can develop the new purposes of clinical tumor on the basis of original function.It is existing that to contain Herba Sarcandrae be extract oral agent and the injection that primary raw material is made, most of China's Chinese medicine preparation of wide clinical application that belongs to, and easy to use, price is more cheap.Extract oral agent and injection that these contain Herba Sarcandrae can be used as in present tumor radiotherapy or the amic therapy method auxiliary therapeutical agent because of the necessity that causes symptom such as thrombocytopenia due to the side effect of cancer therapy drug, after causing immunity of organisms to descend.
Below in conjunction with implementation method the present invention is further described.
The specific embodiment
Embodiment one preparation Herba Sarcandrae fluid extract
Adopt following steps: get raw material Herba Sarcandrae herb decoction pieces by the requirement of Chinese medicine extract technology, decoct with water three times, each two hours, collecting decoction filtered, and filtrate is concentrated into flowing soaking paste, makes every 1g fluid extract be equivalent to raw material Herba Sarcandrae herb decoction pieces 10g.
Embodiment two preparation Herba Sarcandrae dry extracts
Adopt following steps: get the fluid extract of making, become dry extract, make every 1g dry extract be equivalent to raw material Herba Sarcandrae herb decoction pieces 10g at drying under reduced pressure below 85 ℃.
Embodiment three preparation Herba Sarcandrae oral liquids
Adopt following steps: get the Herba Sarcandrae fluid extract or dry extract 125g adds water to 2000ml, the heated and boiled dissolving; Be concentrated into 300ml, add ethanol after the cooling and reach 70% to containing the alcohol amount, left standstill 48 hours, get supernatant and filter, reclaim ethanol, the filtrate adding distil water filters filtrate for later use to 600ml; Get simple syrup 200ml heated and boiled, filtered while hot, filtrate adds in the above-mentioned reserve liquid, adds the 3g sodium benzoate, and adding distil water stirs evenly and promptly gets the Herba Sarcandrae oral liquid to 1000ml, makes every 10ml oral liquid be equivalent to dry extract 1.25g.
Usage and dosage: oral, a 10～20ml, every day 3～4 times.
Embodiment four preparation ZHONGJIEFENG PIAN
Adopt following steps: get Herba Sarcandrae dry extract powder 312.5g, cross 18 mesh sieves, add dry adhesive microcrystalline Cellulose 87.5g, add magnesium stearate lubricant 4.0g, mix homogeneously directly is pressed into 1000, sugar coating promptly gets ZHONGJIEFENG PIAN, makes every to contain Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 0.5mg.
Usage and dosage: oral, one time 3, every day 3 times.
Embodiment five preparation Herba Sarcandrae injection with small volume
Adopt following steps: get raw material Herba Sarcandrae herb decoction pieces 2000g, decoct with water twice after washing, each 2 hours; Merge fried liquid, be concentrated into flowing soaking paste, add triplication ethanol, low-temperature precipitation impurity filters filtrate recycling ethanol; The medicinal liquid ethyl acetate extraction, extract reclaims ethyl acetate, and slight fever is driven most ethyl acetate; Medicinal liquid adds a small amount of water for injection, low temperature sedimentation impurity, filtering precipitation; Transfer pH value to 7.0～8.0, add 0.1% active carbon, be heated with stirring to and boil, add injection water 1000ml, be filtered to clear and bright, embedding, 100 ℃ of flowing steam sterilizations 30 minutes, promptly get the Herba Sarcandrae injection with small volume, every 2ml injection contains raw material Herba Sarcandrae herb decoction pieces and is equivalent to 4g.
Usage and dosage: intramuscular injection, a 2～4ml, every day 1～2 time.
Can be made into high-capacity injection according to the method described above, intravenous injection, once a day, each input quantity is equivalent to contain raw material Herba Sarcandrae herb decoction pieces 4g.
Embodiment six preparation Herba Sarcandrae hard capsules
Adopt following steps: get Herba Sarcandrae dry extract powder 312.5g, sieve, add starch 185g, mix homogeneously is sub-packed in the capsule, makes 1000 of Herba Sarcandrae hard capsules, and every capsule contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 0.5mg.
Usage and dosage: oral, one time 3, every day 3 times.
Embodiment seven preparation sarcandra capsules
Adopt following steps: get Herba Sarcandrae fluid extract 312.5g, after the adding regulator is handled, instil in the capsule material, make 1000 of sarcandra capsules, every capsule contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 0.5mg.
Usage and dosage: oral, one time 3, every day 3 times.
Embodiment eight preparation Herba Sarcandrae microcapsules
Adopt following steps: get Herba Sarcandrae fluid extract 312.5g, after the adding regulator is handled, make it to be dispersed on the corresponding capsule material, make the Herba Sarcandrae microcapsule, pack, every bag of microcapsule contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 1.5mg.
Usage and dosage: oral, one time 1 bag, every day 3 times.
Embodiment nine preparation Herba Sarcandrae electuaries
Adopt following steps: get Herba Sarcandrae fluid extract 937.5g, add excipient Icing Sugar 4500g, starch 4500g sieves, and makes soft material, pelletize, and cold drying, granulate is distributed into 1000 bags, promptly gets the Herba Sarcandrae electuary, and every bagged soluble granules contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 1.5mg.Usage and dosage: warm boiled water, one time 1 bag, every day 3 times.
Claims (8)
1, a kind of application that contains the Herba Sarcandrae Chinese medicine preparation as preparation treatment cancer therapy drug side effect medicine, it is characterized in that: used Herba Sarcandrae Sarcandra glabra (Thunb.) Nakai is a Chloranthaceae Herba Pileae Scriptae platymiscium Herba Pileae Scriptae, get the dry product Herba Sarcandrae and prepare fluid extract or dry extract by the requirement of Chinese medicine leaching preparation process, with Herba Sarcandrae fluid extract or dry extract is that primary raw material is made extract oral agent application, make every 1g fluid extract or dry extract be equivalent to crude drug 10g approximately, use with the Chinese medicine injection with small volume that Herba Sarcandrae extract is made, make every 2ml injection contain crude drug Herba Sarcandrae herb decoction pieces and be equivalent to 4g.
2, the application of preparation according to claim 1 treatment cancer therapy drug side effect medicine is characterized in that: adopt following steps to prepare the Herba Sarcandrae oral liquid: get the Herba Sarcandrae fluid extract or dry extract 125g adds water to 2000ml, the heated and boiled dissolving; Be concentrated into 300ml, add ethanol after the cooling and reach 70% to containing the alcohol amount, left standstill 48 hours, get supernatant and filter, reclaim ethanol, the filtrate adding distil water filters filtrate for later use to 600ml; Get simple syrup 200ml heated and boiled, filtered while hot, filtrate adds in the above-mentioned reserve liquid, adds the 3g sodium benzoate, and adding distil water stirs evenly and promptly gets the Herba Sarcandrae oral liquid to 1000ml, makes every 10ml oral liquid be equivalent to dry extract 1.25g.
3, the application of preparation treatment cancer therapy drug side effect medicine according to claim 1, it is characterized in that: adopt following steps to prepare the Herba Sarcandrae tablet: to get Herba Sarcandrae dry extract powder 312.5g, cross 18 mesh sieves, add dry adhesive microcrystalline Cellulose 87.5g, add magnesium stearate lubricant 4.0g, mix homogeneously, directly be pressed into 1000, sugar coating promptly gets ZHONGJIEFENG PIAN, makes every to contain Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 0.5mg.
4, the application of preparation treatment cancer therapy drug side effect medicine according to claim 1, it is characterized in that: adopt following steps to prepare the Herba Sarcandrae injection with small volume: to take raw material Herba Sarcandrae herb decoction pieces 2000g, decoct with water twice after washing, each 2 hours; Merge fried liquid, be concentrated into flowing soaking paste, add triplication ethanol, low-temperature precipitation impurity filters filtrate recycling ethanol; The medicinal liquid ethyl acetate extraction, extract reclaims ethyl acetate, and slight fever is driven most ethyl acetate; Medicinal liquid adds a small amount of water for injection, low temperature sedimentation impurity, filtering precipitation; Transfer pH value to 7.0～8.0, add 0.1% active carbon, be heated with stirring to and boil, add injection water 1000ml, be filtered to clear and bright, embedding, 100 ℃ of flowing steam sterilizations 30 minutes, promptly get the Herba Sarcandrae injection with small volume, every 2ml injection contains raw material Herba Sarcandrae herb decoction pieces and is equivalent to 4g.
5, the application of preparation treatment cancer therapy drug side effect medicine according to claim 1, it is characterized in that: adopt following steps to prepare electuary: get Herba Sarcandrae fluid extract 937.5g, add excipient Icing Sugar 4500g, starch 4500g, sieve, make soft material, pelletize, cold drying, granulate, be distributed into 1000 bags, promptly get the Herba Sarcandrae electuary, every bagged soluble granules contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 1.5mg.
6, the application of preparation treatment cancer therapy drug side effect medicine according to claim 1, it is characterized in that: adopt following steps to prepare hard capsule: to get Herba Sarcandrae dry extract powder 312.5g, sieve, add starch 185g, mix homogeneously, be sub-packed in the capsule, make 1000 of Herba Sarcandrae hard capsules, every capsule contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 0.5mg.
7, the application of preparation treatment cancer therapy drug side effect medicine according to claim 1, it is characterized in that: adopt following steps to prepare soft capsule: to get Herba Sarcandrae fluid extract 312.5g, after adding the regulator processing, instil in the capsule material, make 1000 of sarcandra capsules, every capsule contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 0.5mg.
8, the application of preparation treatment cancer therapy drug side effect medicine according to claim 1, it is characterized in that: adopt following steps to prepare microcapsule: to get Herba Sarcandrae fluid extract 312.5g, after adding the regulator processing, make it to be dispersed on the corresponding capsule material, make the Herba Sarcandrae microcapsule, pack, every bag of microcapsule contains Herba Sarcandrae with isofraxidin (C
11H
10O
5) count 1.5mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02144873 CN1410110A (en) | 2002-11-19 | 2002-11-19 | Application of Chinese medicine containing sarcandra for treating side effect of anticancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02144873 CN1410110A (en) | 2002-11-19 | 2002-11-19 | Application of Chinese medicine containing sarcandra for treating side effect of anticancer medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1410110A true CN1410110A (en) | 2003-04-16 |
Family
ID=4750689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02144873 Pending CN1410110A (en) | 2002-11-19 | 2002-11-19 | Application of Chinese medicine containing sarcandra for treating side effect of anticancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1410110A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879672B (en) * | 2006-05-17 | 2010-06-16 | 连晓媛 | Effective components of glabrous sarcandra herb - total polyphenol, its preparation method and application |
| CN101543488B (en) * | 2006-05-17 | 2011-03-02 | 连晓媛 | A medicine containing caffeic acid 3,4-dihydroxyl phenethyl ester and its uses |
| CN1954845B (en) * | 2005-10-27 | 2012-03-07 | 山东轩竹医药科技有限公司 | Sarcandra compound medical composite and its preparation method |
| CN101665479B (en) * | 2009-09-22 | 2012-05-16 | 三明华健生物工程有限公司 | Process for synchronously extracting isofraxidin and flavonoid compounds from sarcandra glabra and application thereof |
| CN104127550A (en) * | 2014-08-18 | 2014-11-05 | 青岛市市立医院 | Medicine for treating chemoradiotherapy-induced thrombocytopenia and preparation method thereof |
-
2002
- 2002-11-19 CN CN 02144873 patent/CN1410110A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954845B (en) * | 2005-10-27 | 2012-03-07 | 山东轩竹医药科技有限公司 | Sarcandra compound medical composite and its preparation method |
| CN1879672B (en) * | 2006-05-17 | 2010-06-16 | 连晓媛 | Effective components of glabrous sarcandra herb - total polyphenol, its preparation method and application |
| CN101543488B (en) * | 2006-05-17 | 2011-03-02 | 连晓媛 | A medicine containing caffeic acid 3,4-dihydroxyl phenethyl ester and its uses |
| CN101665479B (en) * | 2009-09-22 | 2012-05-16 | 三明华健生物工程有限公司 | Process for synchronously extracting isofraxidin and flavonoid compounds from sarcandra glabra and application thereof |
| CN104127550A (en) * | 2014-08-18 | 2014-11-05 | 青岛市市立医院 | Medicine for treating chemoradiotherapy-induced thrombocytopenia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN1302796C (en) | Traditional Chinese medicament for treating woman subhealthy faligue syndrome and its preparation method | |
| CN105796861A (en) | Application of forsythin, forsythin derivatives and composition of forsythin and forsythiaside to preparation of drug for improving immune function | |
| CN1410110A (en) | Application of Chinese medicine containing sarcandra for treating side effect of anticancer medicine | |
| CN101347543A (en) | Chinese medicine compound and preparation method thereof | |
| CN1899448A (en) | Chinese medicine compound preparation for treating amblyopia and its preparing method | |
| CN107854565B (en) | Anti-radiation traditional Chinese medicine composition | |
| CN1943718B (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN1931276A (en) | Headache treating Chinese medicine composition and its prepn process | |
| CN1943620A (en) | Chinese medicine composition for treating cardio-cerabral vascular diseases and its preparing method | |
| CN1270755C (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1264547C (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method | |
| CN101032524A (en) | Application of martianus dermestoides in producing oxygen-deficient resisting medicine or healthy food and the preparing method | |
| CN1289111C (en) | Medicine for lowering blood lipid and softening blood vessel and its preparing method | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN1226045C (en) | Medicine for treating headache | |
| CN1785264A (en) | Chinese medicinal composition for treating strangury patterns and preparation method of its oral liquid, tablet and capsule | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation | |
| AU2021100051A4 (en) | Antitumor formula and extraction method thereof | |
| CN108404059A (en) | A kind of Chinese medicine composition for treating anti-type thyroid adenoma on liver-yang | |
| CN1274320C (en) | Notoginseng ginkgo health care food and its preparation method | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process | |
| CN1943677A (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN1943732A (en) | A medicinal composition for treatment of psoriasis | |
| CN1256083C (en) | Medicine for boosting qi and nourishing blood and its prepatation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |